The explosion of semaglutide prescribing has extended well beyond middle-aged adults managing metabolic disease — it has now reached teenagers and young adults at a scale that outpaces the available long-term safety evidence for this age group. That gap between clinical uptake and evidence base is what makes this Danish registry analysis particularly important for anyone tracking the long-term implications of GLP-1 therapeutics.
Drawing on Denmark's comprehensive nationwide prescription, hospital, and laboratory registries, researchers tracked every GLP-1 receptor agonist prescription filled by individuals aged 12 to 24 between January 2018 and December 2025. Incidence of new use surged more than 50-fold over that window, reaching 418 new users per 100,000 by 2025. The sharpest acceleration occurred in the 18-to-24 cohort, climbing from 13 to 686 per 100,000 — a nearly fiftyfold increase — while adolescents aged 12 to 17 saw a more restrained but still striking rise, from 1.7 to 72 per 100,000. Semaglutide for weight management drove the majority of prescriptions. Most users were female, relatively few carried a diabetes diagnosis, and one-third presented with psychiatric comorbidity, predominantly emotional and neurodevelopmental disorders. By 2025, general practitioners — rather than obesity specialists or endocrinologists — were initiating 78% of new treatments. Crucially, treatment persistence was low: only 38% of new users remained on therapy after one year.
These findings carry several important implications beyond the headline growth numbers. The high rate of psychiatric comorbidity is a clinically significant signal; GLP-1 receptor agonists have been associated in some post-marketing data with mood changes, and their neuropsychiatric effects in developing adolescent brains remain poorly characterized. The dominance of general practice prescribing, while reflecting broader healthcare access, raises questions about whether systematic mental health screening and specialist oversight are being applied consistently. The low one-year persistence rate also suggests that real-world weight management outcomes in youth may diverge substantially from the robust efficacy seen in controlled trials. This study is observational and country-specific, limiting causal inference and generalizability, but Denmark's registry infrastructure makes the utilization trends exceptionally reliable. Considered alongside parallel data emerging from the United States and elsewhere, this finding is best characterized as an important surveillance signal — not alarming, but warranting accelerated long-term safety research in younger populations.